Hepatobiliary manifestations of critically ill and postoperative patients

Clinics in Liver Disease

Volumn 15, Issue 1, 2011, Pages 183-197

  Aronsohn, Andrew ^a   Jensen, Donald ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Critical illness; Hypoxic liver injury; Post operative liver dysfunction; Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DESFLURANE; ENFLURANE; GLUCOSE; HALOTHANE; INTERLEUKIN 6; ISOFLURANE; LACTATE DEHYDROGENASE; SEVOFLURANE; TUMOR NECROSIS FACTOR ALPHA;

ACALCULOUS CHOLECYSTITIS; ACUTE HEART FAILURE; ACUTE HEPATITIS; ACUTE RESPIRATORY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANESTHESIA COMPLICATION; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT DISEASE; CHOLESTASIS; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEVER; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HEMOLYSIS; HEPATOMEGALY; HUMAN; HYPOXIC LIVER INJURY; JAUNDICE; KUPFFER CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER HISTOLOGY; LIVER INJURY; LIVER ISCHEMIA; LIVER TRANSPLANTATION; NEUTROPHIL; PERFUSION; POSTOPERATIVE PERIOD; PROTEIN SYNTHESIS; REVIEW; RISK REDUCTION; SEPSIS; SURGICAL PATIENT; TOTAL PARENTERAL NUTRITION; UPPER ABDOMINAL PAIN;

BILIARY TRACT DISEASES; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; LIVER DISEASES; POSTOPERATIVE PERIOD;

EID: 78649519492     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.09.004     Document Type: Review

References (89)

1. Kramer L., Jordan B., Druml W., et al. Incidence and prognosis of early hepatic dysfunction in critically ill patients-a prospective multicenter study. Crit Care Med 2007, 35(4):1099-1104.
2. Bynum T.E., Boitnott J.K., Maddrey W.C. Ischemic hepatitis. Dig Dis Sci 1979, 24(2):129-135.
3. Arcidi J.M., Moore G.W., Hutchins G.M. Hepatic morphology in cardiac dysfunction: a clinicopathologic study of 1000 subjects at autopsy. Am J Pathol 1981, 104(2):159-166.
4. Henrion J., Schapira M., Luwaert R., et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003, 82(6):392-406.
5. Henrion J., Schapira M., Heller F.R. Ischemic hepatitis: the need for precise criteria. J Clin Gastroenterol 1996, 23(4):305.
6. Kamiyama T., Miyakawa H., Tajiri K., et al. Ischemic hepatitis in cirrhosis. clinical features and prognostic implications. J Clin Gastroenterol 1996, 22(2):126-130.
7. Birrer R., Takuda Y., Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007, 46(14):1063-1070.
8. Ebert E.C. Hypoxic liver injury. Mayo Clin Proc 2006, 81(9):1232-1236.
9. Henrion J., Descamps O., Luwaert R., et al. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 1994, 21(5):696-703.
10. Seeto R.K., Fenn B., Rockey D.C. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000, 109(2):109-113.
11. Batin P., Wickens M., McEntegart D., et al. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995, 16(11):1613-1618.
12. Myers R.P., Cerini R., Sayegh R., et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003, 37(2):393-400.
13. Fuhrmann V., Kneidinger N., Herkner H., et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009, 35(8):1397-1405.
14. Henrion J., Minette P., Colin L., et al. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999, 29(2):427-433.
15. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-1655.
16. Plank L.D., Hill G.L. Sequential metabolic changes following induction of systemic inflammatory response in patients with severe sepsis or major blunt trauma. World J Surg 2000, 24(6):630-638.
17. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29(7):1303-1310.
18. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274(12):968-974.
19. Finfer S., Bellomo R., Lipman J., et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004, 30(4):589-596.
20. Mathison J.C., Ulevitch R.J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979, 123(5):2133-2143.
21. Pastor C.M., Billiar T.R., Losser M.R., et al. Liver injury during sepsis. J Crit Care 1995, 10(4):183-197.
22. Szabo G., Romics L., Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis 2002, 6(4):1045-1066. x.
23. Van Oosten M., Rensen P.C., Van Amersfoort E.S., et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001, 276(12):8820-8824.
24. Naito M., Hasegawa G., Ebe Y., et al. Differentiation and function of Kupffer cells. Med Electron Microsc 2004, 37(1):16-28.
25. Katz S., Jimenez M.A., Lehmkuhler W.E., et al. Liver bacterial clearance following hepatic artery ligation and portacaval shunt. J Surg Res 1991, 51(3):267-270.
26. Matuschak G.M., Rinaldo J.E. Organ interactions in the adult respiratory distress syndrome during sepsis. Role of the liver in host defense. Chest 1988, 94(2):400-406.
27. Fernandez J., Navasa M., Gomez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35(1):140-148.
28. Gustot T., Durand F., Lebrec D., et al. Severe sepsis in cirrhosis. Hepatology 2009, 50(6):2022-2033.
29. Foreman M.G., Mannino D.M., Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003, 124(3):1016-1020.
30. Singh N., Gayowski T., Wagener M.M., et al. Outcome of patients with cirrhosis requiring intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol 1998, 33(1):73-79.
31. Aggarwal A., Ong J.P., Younossi Z.M., et al. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001, 119(5):1489-1497.
32. Zauner C., Schneeweiss B., Schneider B., et al. Short-term prognosis in critically ill patients with liver cirrhosis: an evaluation of a new scoring system. Eur J Gastroenterol Hepatol 2000, 12(5):517-522.
33. Dahn M.S., Lange P., Lobdell K., et al. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery 1987, 101(1):69-80.
34. Dhainaut J.F., Marin N., Mignon A., et al. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001, 29(Suppl 7):S42-S47.
35. Maynard N.D., Bihari D.J., Dalton R.N., et al. Liver function and splanchnic ischemia in critically ill patients. Chest 1997, 111(1):180-187.
36. Doi F., Goya T., Torisu M. Potential role of hepatic macrophages in neutrophil-mediated liver injury in rats with sepsis. Hepatology 1993, 17(6):1086-1094.
37. Marshall J.C. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001, 29(Suppl 7):S99-106.
38. Chand N., Sanyal A.J. Sepsis-induced cholestasis. Hepatology 2007, 45(1):230-241.
39. Whitehead M.W., Hainsworth I., Kingham J.G. The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001, 48(3):409-413.
40. te Boekhorst T., Urlus M., Doesburg W., et al. Etiologic factors of jaundice in severely ill patients. A retrospective study in patients admitted to an intensive care unit with severe trauma or with septic intra-abdominal complications following surgery and without evidence of bile duct obstruction. J Hepatol 1988, 7(1):111-117.
41. Vermillion S.E., Gregg J.A., Baggenstoss A.H., et al. Jaundice associated with bacteremia. Arch Intern Med 1969, 124(5):611-618.
42. Hawker F. Liver dysfunction in critical illness. Anaesth Intensive Care 1991, 19(2):165-181.
43. Batge B., Filejski W., Kurowski V., et al. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med 1992, 18(8):488-490.
44. Berkowitz F.E. Hemolysis and infection: categories and mechanisms of their interrelationship. Rev Infect Dis 1991, 13(6):1151-1162.
45. Shander A. Anemia in the critically ill. Crit Care Clin 2004, 20(2):159-178.
46. Arndt P.A., Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005, 42(3):137-144.
47. Karmali M.A., Petric M., Lim C., et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985, 151(5):775-782.
48. Koster F., Levin J., Walker L., et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med 1978, 298(17):927-933.
49. Spolarics Z., Condon M.R., Siddiqi M., et al. Red blood cell dysfunction in septic glucose-6-phosphate dehydrogenase-deficient mice. Am J Physiol Heart Circ Physiol 2004, 286(6):H2118-H2126.
50. Roelofsen H., van der Veere C.N., Ottenhoff R., et al. Decreased bilirubin transport in the perfused liver of endotoxemic rats. Gastroenterology 1994, 107(4):1075-1084.
51. Nolan J.P. Intestinal endotoxins as mediators of hepatic injury-an idea whose time has come again. Hepatology 1989, 10(5):887-891.
52. Wang P., Chaudry I.H. Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Am J Physiol 1996, 270(5 Pt 2):R927-R938.
53. Elferink M.G., Olinga P., Draaisma A.L., et al. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am J Physiol Gastrointest Liver Physiol 2004, 287(5):G1008-G1016.
54. Geier A., Fickert P., Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol 2006, 3(10):574-585.
55. Strazzabosco M., Fabris L., Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005, 39(4 Suppl 2):S90-S102.
56. Spirli C., Nathanson M.H., Fiorotto R., et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001, 121(1):156-169.
57. Benninger J., Grobholz R., Oeztuerk Y., et al. Sclerosing cholangitis following severe trauma: description of a remarkable disease entity with emphasis on possible pathophysiologic mechanisms. World J Gastroenterol 2005, 11(27):4199-4205.
58. Engler S., Elsing C., Flechtenmacher C., et al. Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut 2003, 52(5):688-693.
59. Moseley R.H. Sepsis and cholestasis. Clin Liver Dis 2004, 8(1):83-94.
60. Faust T.W., Reddy K.R. Postoperative jaundice. Clin Liver Dis 2004, 8(1):151-166.
61. LaMont J.T., Isselbacher K.J. Current concepts of postoperative hepatic dysfunction. Conn Med 1975, 39(8):461-464.
62. Molina E.G., Reddy K.R. Postoperative jaundice. Clin Liver Dis 1999, 3(3):477-488.
63. Berg C., Crawford J., Gollan J. Bilirubin metabolism and the pathophysiology of jaundice. Schiff's diseases of the liver 1998, 147-192. Lippincott-Raven, Philadelphia. 8th edition. S. ER, S. MF, M. WC (Eds.).
64. Ketterhagen J., Quackenbush S. Hyperbilirubinemia of fasting. A case of postoperative jaundice. Arch Surg 1983, 118(6):756-758.
65. Schmid M., Hefti M.L., Gattiker R., et al. Benign postoperative intrahepatic cholestasis. N Engl J Med 1965, 272:545-550.
66. Kantrowitz P.A., Jones W.A., Greenberger N.J., et al. Severe postoperative hyperbilirubinemia simulating obstructive jaundice. N Engl J Med 1967, 276(11):590-598.
67. Barie P.S., Fischer E. Acute acalculous cholecystitis. J Am Coll Surg 1995, 180(2):232-244.
68. Orlando R., Gleason E., Drezner A.D. Acute acalculous cholecystitis in the critically ill patient. Am J Surg 1983, 145(4):472-476.
69. Mirvis S.E., Vainright J.R., Nelson A.W., et al. The diagnosis of acute acalculous cholecystitis: a comparison of sonography, scintigraphy, and CT. AJR Am J Roentgenol 1986, 147(6):1171-1175.
70. Blankenberg F., Wirth R., Jeffrey R.B., et al. Computed tomography as an adjunct to ultrasound in the diagnosis of acute acalculous cholecystitis. Gastrointest Radiol 1991, 16(2):149-153.
71. Fox M.S., Wilk P.J., Weissmann H.S., et al. Acute acalculous cholecystitis. Surg Gynecol Obstet 1984, 159(1):13-16.
72. Bunker J., Forrest W., Mosteller F. National Halothane Study. A study of the possible association between halothane anesthesia and postoperative hepatic necrosis 1969, Government Printing Office, Washington, DC.
73. Wiklund R.A., Rosenbaum S.H. Anesthesiology. First of two parts. N Engl J Med 1997, 337(16):1132-1141.
74. Warner L.O., Beach T.P., Garvin J.P., et al. Halothane and children: the first quarter century. Anesth Analg 1984, 63(9):838-840.
75. Walton B., Simpson B.R., Strunin L., et al. Unexplained hepatitis following halothane. Br Med J 1976, 1(6019):1171-1176.
76. Benjamin S.B., Goodman Z.D., Ishak K.G., et al. The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology 1985, 5(6):1163-1171.
77. Wright R., Eade O.E., Chisholm M., et al. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975, 1(7911):817-820.
78. Holt C., Csete M., Martin P. Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroenterol Clin North Am 1995, 24(4):853-874.
79. Brown B.R., Gandolfi A.J. Adverse effects of volatile anaesthetics. Br J Anaesth 1987, 59(1):14-23.
80. Lo S.K., Wendon J., Mieli-Vergani G., et al. Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. Eur J Gastroenterol Hepatol 1998, 10(8):635-639.
81. Nishiyama T., Yokoyama T., Hanaoka K. Liver and renal function after repeated sevoflurane or isoflurane anaesthesia. Can J Anaesth 1998, 45(8):789-793.
82. Brunt E.M., White H., Marsh J.W., et al. Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: a case report. Hepatology 1991, 13(6):1017-1021.
83. Lewis J.H., Zimmerman H.J., Ishak K.G., et al. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983, 98(6):984-992.
84. Grau T., Bonet A., Rubio M., et al. Liver dysfunction associated with artificial nutrition in critically ill patients. Crit Care 2007, 11(1):R10.
85. Chung C., Buchman A.L. Postoperative jaundice and total parenteral nutrition-associated hepatic dysfunction. Clin Liver Dis 2002, 6(4):1067-1084.
86. MacFadyen B.V., Dudrick S.J., Baquero G., et al. Clinical and biological changes in liver function during intravenous hyperalimentation. JPEN J Parenter Enteral Nutr 1979, 3(6):438-443.
87. Leaseburge L.A., Winn N.J., Schloerb P.R. Liver test alterations with total parenteral nutrition and nutritional status. JPEN J Parenter Enteral Nutr 1992, 16(4):348-352.
88. Pappo I., Bercovier H., Berry E.M., et al. Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. JPEN J Parenter Enteral Nutr 1992, 16(6):529-532.
89. Baker A.L., Rosenberg I.H. Hepatic complications of total parenteral nutrition. Am J Med 1987, 82(3):489-497.